Naldemedine for the treatment of opioid-induced constipation in adults with chronic noncancer pain.
Pain Manag
; 10(5): 301-306, 2020 Sep.
Article
em En
| MEDLINE
| ID: mdl-32552565
ABSTRACT
This review aims to summarize the efficacy data for naldemedine, a member of the novel peripherally acting µ-opioid receptor antagonists (PAMORAs), which gained US FDA approval for the treatment of opioid-induced constipation in adults with chronic noncancer pain-related syndromes in 2017. In Phase III trials, patients receiving naldemedine were significantly more likely to meet the primary end point ≥3 spontaneous bowel movements/week and an increase of ≥1 spontaneous bowel movement/week from baseline for at least 9/12 weeks compared to placebo (p < 0.0001). The most frequent adverse events were abdominal pain (8%) and diarrhea (7%). Based on available data, naldemedine appears to be an effective and safe first-line therapy for the treatment of opioid-induced constipation in adults with chronic noncancer pain.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dor Crônica
/
Constipação Induzida por Opioides
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article